论文部分内容阅读
目的评价培美曲塞联合顺铂(PC方案)和多西他塞联合顺铂(DP方案)治疗非小细胞肺癌(NSCLC)的疗效。方法 78例NSCLC患者随机分为两组:A组38例,采用PC方案,B组40例,采用DP方案。比较两组近期疗效。结果A、B组有效率相仿(34.21%vs.42.50%)(P>0.05)。A、B组疾病控制率相仿(73.68%vs.80.00%)(P>0.05)。A组主要不良反应如恶心呕吐(47.36%vs.75.00%)、肝功能异常(39.47%vs.72.50%)、中性粒细胞减少(36.84%vs.75.00%)和脱发(10.53%vs.90.00%)的发生率均低于B组(P<0.05)。随访1年后,A、B组的生存率分别为26.31%和32.50%,中位生存期分别为5个月和11个月。结论 PC方案和DP方案治疗晚期NSCLC的近期疗效大致相仿,但是PC方案的不良反应发生率较低。
Objective To evaluate the efficacy of pemetrexed combined with cisplatin (PC) and docetaxel combined with cisplatin (DP) in the treatment of non-small cell lung cancer (NSCLC). Methods Seventy-eight patients with NSCLC were randomly divided into two groups: A group (38 cases), PC group (40 cases) and DP group (40 cases). Compare the two groups of recent curative effect. Results The effective rates in groups A and B were similar (34.21% vs.42.50%) (P> 0.05). The disease control rates in group A and group B were similar (73.68% vs. 80.00%) (P> 0.05). A group of major adverse reactions such as nausea and vomiting (47.36% vs.75.00%), abnormal liver function (39.47% vs.72.50%), neutropenia (36.84% vs.75.00%) and hair loss (10.53% vs.90.00 %) Were lower than those in group B (P <0.05). After one year of follow-up, the survival rates in groups A and B were 26.31% and 32.50%, respectively. The median survival time was 5 months and 11 months respectively. Conclusion The PC and DP regimens in the treatment of advanced non-small cell lung cancer (NSCLC) have similar long-term effects, but the PC program has a lower incidence of adverse reactions.